EP1735020A1 - Alginates reticules et non reticules, injectables, et leur utilisation en medecine et en chirurgie esthetique - Google Patents
Alginates reticules et non reticules, injectables, et leur utilisation en medecine et en chirurgie esthetiqueInfo
- Publication number
- EP1735020A1 EP1735020A1 EP05707688A EP05707688A EP1735020A1 EP 1735020 A1 EP1735020 A1 EP 1735020A1 EP 05707688 A EP05707688 A EP 05707688A EP 05707688 A EP05707688 A EP 05707688A EP 1735020 A1 EP1735020 A1 EP 1735020A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alginate
- use according
- crosslinked
- solution
- microcapsules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 235000010443 alginic acid Nutrition 0.000 title claims abstract description 100
- 229920000615 alginic acid Polymers 0.000 title claims abstract description 100
- 239000003814 drug Substances 0.000 title claims description 9
- 238000002316 cosmetic surgery Methods 0.000 title description 2
- 238000011282 treatment Methods 0.000 claims abstract description 39
- 239000003094 microcapsule Substances 0.000 claims abstract description 38
- 206010046543 Urinary incontinence Diseases 0.000 claims abstract description 23
- 206010047370 Vesicoureteric reflux Diseases 0.000 claims abstract description 12
- 150000001768 cations Chemical class 0.000 claims abstract description 12
- 201000008618 vesicoureteral reflux Diseases 0.000 claims abstract description 12
- 208000031355 vesicoureteral reflux 1 Diseases 0.000 claims abstract description 12
- 239000011859 microparticle Substances 0.000 claims abstract description 7
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 74
- 229940072056 alginate Drugs 0.000 claims description 73
- 238000002347 injection Methods 0.000 claims description 52
- 239000007924 injection Substances 0.000 claims description 52
- 239000000243 solution Substances 0.000 claims description 45
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 22
- 210000003205 muscle Anatomy 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 17
- 239000002775 capsule Substances 0.000 claims description 15
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 14
- 229910052788 barium Inorganic materials 0.000 claims description 14
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 14
- 239000011575 calcium Substances 0.000 claims description 14
- 238000002513 implantation Methods 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 229910052791 calcium Inorganic materials 0.000 claims description 11
- 238000011065 in-situ storage Methods 0.000 claims description 11
- 238000010992 reflux Methods 0.000 claims description 11
- 210000005070 sphincter Anatomy 0.000 claims description 11
- 238000004132 cross linking Methods 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 239000008139 complexing agent Substances 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000000737 potassium alginate Substances 0.000 claims description 2
- 235000010408 potassium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 159000000007 calcium salts Chemical class 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229940005550 sodium alginate Drugs 0.000 claims 1
- 239000000499 gel Substances 0.000 abstract description 21
- 208000021302 gastroesophageal reflux disease Diseases 0.000 abstract description 14
- 230000037303 wrinkles Effects 0.000 abstract description 13
- 230000007547 defect Effects 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 24
- 108010035532 Collagen Proteins 0.000 description 19
- 102000008186 Collagen Human genes 0.000 description 19
- 229920001436 collagen Polymers 0.000 description 15
- 206010040954 Skin wrinkling Diseases 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 12
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000000501 collagen implant Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 229920002674 hyaluronan Polymers 0.000 description 9
- 229960003160 hyaluronic acid Drugs 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 229920001222 biopolymer Polymers 0.000 description 8
- 230000007774 longterm Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 7
- 241000195493 Cryptophyta Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 210000003238 esophagus Anatomy 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 239000004971 Cross linker Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 108010020199 glutaraldehyde-cross-linked collagen Proteins 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010021639 Incontinence Diseases 0.000 description 3
- 229920001954 Restylane Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 210000004211 gastric acid Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- -1 polytetrafluoroethylenes Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010023424 Kidney infection Diseases 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 206010037596 Pyelonephritis Diseases 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000035606 childbirth Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 208000024798 heartburn Diseases 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 210000000111 lower esophageal sphincter Anatomy 0.000 description 2
- 210000003903 pelvic floor Anatomy 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-AZLKCVHYSA-N (2r,3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-AZLKCVHYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 description 1
- 229920001605 Dextranomer Polymers 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108010072959 Fibrel Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 108010045569 atelocollagen Proteins 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Inorganic materials [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000007728 cost analysis Methods 0.000 description 1
- 229940070259 deflux Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002638 denervation Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 229960002864 dextranomer Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940079920 digestives acid preparations Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 208000028653 esophageal adenocarcinoma Diseases 0.000 description 1
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 108010021426 hylan gel Proteins 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- HWGNBUXHKFFFIH-UHFFFAOYSA-I pentasodium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O HWGNBUXHKFFFIH-UHFFFAOYSA-I 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000019832 sodium triphosphate Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
Definitions
- the chemical denervation eg by Botulmumtoxm A
- the surface leveling and on the third the treatment with "fillers” - the dermis is relined with endogenous or foreign substances.
- the present invention describes the novel use of alginates for the application as "F ⁇ ller M substance.
- foreign fillers which mainly consist of biological substances such as collagen or hyaluronic acid (eg: collagen: Zyderm ® , Zyplast ® , Atelocollagen ® , Resoplast ® ® .
- Hyaluronic acid is a mucopolysaccharide that is found in almost every part of a living organism and especially in the skin. Chemically, hyaluronic acid is made from straight polymer chains. ten with a molecular weight in the range of several hundred thousand to million daltons, which contain repeating disaccharide units from N-acetylglucosamine and glucuronic acid, which are linked together by glycosidic bonds.
- GSD gastroesophageal reflux disease
- Gastroosophageal reflux disease describes the backflow of acidic, enzymatic fluid from the stomach to the esophagus. It causes heartburn , Regurgitation and vomiting of gastric acid in the mouth or even in the lungs.
- the consequences of "GERD” are burns of the esophagus and the formation of ulcers, whereby the normal epithelial tissue is replaced by pathological tissue.
- the lower oesophageal sphincter muscle closes after eating. This does not happen in patients suffering from “GERD”, instead the muscle relaxes and the gastric acid can flow through the esophagus if the stomach contracts. This is the main cause of "GERD”, other causes are possible.
- the material should be injectable through a narrow cannula without the geometric shapes, e.g. Microcapsules are destroyed. 2. The material must be so variable for the different applications that short to long-term stability can be achieved in vivo. 3. The material should remain at the injection site and not migrate. 4. The material should be soluble in an emergency or after the end of the indication. 5. The material must be biocompatible.
- the alkali salts of the alginates are water-soluble, while the salts of the alginates with most divalent or polyvalent cations form insoluble gels (so-called hydrogels) in aqueous solution.
- the large physical range of variation of the alginates is given by a number of factors: viscosity (or molecular weight distribution), concentration, ratio of the monomers and the affinity of the cation used for the crosslinking. For example, it is known that alginates cross-linked with calcium form less stable hydrogels than alginates cross-linked with barium.
- substances can also be added to the algmat or covalently bound to the alginate which create a histological connection after the injection between the algmat capsules or the algae gel and the surrounding tissue.
- adhesion proteins eg RGD tripeptides.
- the microcapsules for the treatment of urinary incontinence and the vesico-ureteral reflux disease are injected into the ureteral sphincter, the bladder sphincter or the urethral muscles.
- the sphincter volume increases in proportion to the volume of the microcapsules injected. This reduces the inner lumen of the sphincter muscle and allows a better contraction of the muscle, which reduces the likelihood of urinary incontinence.
- other forms of use described above can also be used, e.g. B. Injection of calcium crosslinked microcapsules from alginate or injection of uncrosslinked algae gel with and without methods for in situ crosslinking.
- the implantation should preferably be carried out using standard techniques which correspond to the state of the art, e.g. endoscopic or laparoscopic techniques.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004019241A DE102004019241A1 (de) | 2004-04-16 | 2004-04-16 | Injizierbare vernetzte und unvernetzte Alginate und ihre Verwendung in der Medizin und in der ästhetischen Chirurgie |
| PCT/EP2005/002201 WO2005105167A1 (fr) | 2004-04-16 | 2005-03-02 | Alginates reticules et non reticules, injectables, et leur utilisation en medecine et en chirurgie esthetique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1735020A1 true EP1735020A1 (fr) | 2006-12-27 |
Family
ID=34961026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP05707688A Withdrawn EP1735020A1 (fr) | 2004-04-16 | 2005-03-02 | Alginates reticules et non reticules, injectables, et leur utilisation en medecine et en chirurgie esthetique |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8163714B2 (fr) |
| EP (1) | EP1735020A1 (fr) |
| BR (1) | BRPI0509924A (fr) |
| DE (1) | DE102004019241A1 (fr) |
| WO (1) | WO2005105167A1 (fr) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004019241A1 (de) | 2004-04-16 | 2005-11-03 | Cellmed Ag | Injizierbare vernetzte und unvernetzte Alginate und ihre Verwendung in der Medizin und in der ästhetischen Chirurgie |
| DE102005037026B4 (de) * | 2005-08-05 | 2010-12-16 | Cavitator Systems Gmbh | Kavitationsmischer |
| CN101578520B (zh) | 2006-10-18 | 2015-09-16 | 哈佛学院院长等 | 基于形成图案的多孔介质的横向流动和穿过生物测定装置、及其制备方法和使用方法 |
| MX2009009710A (es) * | 2007-03-13 | 2009-10-30 | Biolinerx Ltd | Un metodo para promover la preparacion de tejido. |
| KR100902781B1 (ko) * | 2007-10-05 | 2009-06-12 | (주)라이프코드 | 일체형 무균 캡슐 제조장치 |
| CN101925399A (zh) * | 2007-11-30 | 2010-12-22 | 巴斯夫欧洲公司 | 用于调制含可磁化颗粒的悬浮液的方法和设备 |
| US9044477B2 (en) * | 2007-12-12 | 2015-06-02 | Allergan, Inc. | Botulinum toxin formulation |
| US8387599B2 (en) | 2008-01-07 | 2013-03-05 | Mcalister Technologies, Llc | Methods and systems for reducing the formation of oxides of nitrogen during combustion in engines |
| US8074625B2 (en) | 2008-01-07 | 2011-12-13 | Mcalister Technologies, Llc | Fuel injector actuator assemblies and associated methods of use and manufacture |
| US8225768B2 (en) | 2008-01-07 | 2012-07-24 | Mcalister Technologies, Llc | Integrated fuel injector igniters suitable for large engine applications and associated methods of use and manufacture |
| US7628137B1 (en) | 2008-01-07 | 2009-12-08 | Mcalister Roy E | Multifuel storage, metering and ignition system |
| WO2011071608A2 (fr) | 2009-12-07 | 2011-06-16 | Mcalister Roy E | Système de commande adaptatif pour injecteurs de carburant et dispositifs d'allumage |
| US8635985B2 (en) | 2008-01-07 | 2014-01-28 | Mcalister Technologies, Llc | Integrated fuel injectors and igniters and associated methods of use and manufacture |
| US8413634B2 (en) | 2008-01-07 | 2013-04-09 | Mcalister Technologies, Llc | Integrated fuel injector igniters with conductive cable assemblies |
| US8561598B2 (en) | 2008-01-07 | 2013-10-22 | Mcalister Technologies, Llc | Method and system of thermochemical regeneration to provide oxygenated fuel, for example, with fuel-cooled fuel injectors |
| US8365700B2 (en) | 2008-01-07 | 2013-02-05 | Mcalister Technologies, Llc | Shaping a fuel charge in a combustion chamber with multiple drivers and/or ionization control |
| EP2082755A1 (fr) * | 2008-01-16 | 2009-07-29 | CellMed AG | Implants in situ d'alginate en réseau monolithiques |
| CN102132398B (zh) | 2008-03-21 | 2015-01-28 | 哈佛学院院长等 | 用于互连的自对准阻挡层 |
| WO2009121041A2 (fr) * | 2008-03-27 | 2009-10-01 | President And Fellows Of Harvard College | Systèmes microfluidiques à base de papier |
| CA2719322C (fr) * | 2008-03-27 | 2018-11-27 | President And Fellows Of Harvard College | Fil de coton servant de plate-forme diagnostique pour analyses multiples a bas couts |
| EP2257819A4 (fr) * | 2008-03-27 | 2017-10-11 | President and Fellows of Harvard College | Dispositifs microfluidiques tridimensionnels |
| CN101978272B (zh) * | 2008-03-27 | 2015-02-04 | 哈佛学院院长等 | 基于纸的细胞阵列 |
| WO2009121038A2 (fr) * | 2008-03-27 | 2009-10-01 | President And Fellows Of Harvard College | Films conformés d'hydrogels fabriqués à l'aide de modèles de papier texturé |
| DE102008016998A1 (de) * | 2008-04-03 | 2009-10-08 | GÖPFERICH, Achim, Prof. Dr. | Langsam lösliche quervernetzte Matrices zur Verabreichung von Proteinarzneistoffen |
| US8042989B2 (en) * | 2009-05-12 | 2011-10-25 | Cavitation Technologies, Inc. | Multi-stage cavitation device |
| US8603198B2 (en) | 2008-06-23 | 2013-12-10 | Cavitation Technologies, Inc. | Process for producing biodiesel through lower molecular weight alcohol-targeted cavitation |
| US7762715B2 (en) * | 2008-10-27 | 2010-07-27 | Cavitation Technologies, Inc. | Cavitation generator |
| US8894273B2 (en) * | 2008-10-27 | 2014-11-25 | Roman Gordon | Flow-through cavitation-assisted rapid modification of crude oil |
| US8709750B2 (en) * | 2008-12-15 | 2014-04-29 | Cavitation Technologies, Inc. | Method for processing an algae medium containing algae microorganisms to produce algal oil and by-products |
| US9199841B2 (en) * | 2009-01-26 | 2015-12-01 | Advanced Fiber Technologies, Inc. | Method for disentanglement of carbon nanotube bundles |
| US9192933B2 (en) | 2009-03-06 | 2015-11-24 | President And Fellows Of Harvard College | Microfluidic, electrochemical devices |
| WO2010117266A1 (fr) | 2009-04-06 | 2010-10-14 | Broockeville Corporation N.V. | Systèmes de gélification in situ à base d'alginate |
| US9988651B2 (en) | 2009-06-15 | 2018-06-05 | Cavitation Technologies, Inc. | Processes for increasing bioalcohol yield from biomass |
| US9611496B2 (en) | 2009-06-15 | 2017-04-04 | Cavitation Technologies, Inc. | Processes for extracting carbohydrates from biomass and converting the carbohydrates into biofuels |
| EP2470775B1 (fr) | 2009-08-27 | 2015-04-29 | McAlister Technologies, LLC | Mise en forme d'une charge de carburant dans une chambre de combustion à l'aide de plusieurs systèmes d'entraînement et/ou de commande d'ionisation |
| CN102712540B (zh) | 2009-08-27 | 2014-12-17 | 麦卡利斯特技术有限责任公司 | 陶瓷绝缘体及其使用和制造方法 |
| AU2010310750B2 (en) * | 2009-10-23 | 2015-02-26 | President And Fellows Of Harvard College | Self-aligned barrier and capping layers for interconnects |
| WO2011071607A2 (fr) | 2009-12-07 | 2011-06-16 | Mcalister Roy E | Allumeurs d'injecteur de carburant intégrés pour applications moteur importantes et procédés associés d'utilisation et de fabrication |
| FR2955258A1 (fr) | 2010-01-20 | 2011-07-22 | Biopharmex Holding Ltd | Composition injectable |
| CN102821861B (zh) | 2010-02-03 | 2015-03-25 | 哈佛大学校长及研究员协会 | 用于多重测定的装置和方法 |
| KR101245398B1 (ko) | 2010-02-13 | 2013-03-19 | 맥알리스터 테크놀로지즈 엘엘씨 | 음파 변경기를 갖는 연료 분사기 조립체 및 관련 사용 및 제조 방법 |
| EP2534347B1 (fr) | 2010-02-13 | 2016-05-04 | McAlister, Roy Edward | Procédés et systèmes de refroidissement adaptatif de chambres de combustion dans des moteurs |
| US20110297753A1 (en) | 2010-12-06 | 2011-12-08 | Mcalister Roy E | Integrated fuel injector igniters configured to inject multiple fuels and/or coolants and associated methods of use and manufacture |
| WO2011124381A1 (fr) | 2010-04-08 | 2011-10-13 | Merz Pharma Gmbh & Co. Kgaa | Charges comprenant des billes de gellane ou de pectine |
| WO2011124380A1 (fr) | 2010-04-08 | 2011-10-13 | Merz Pharma Gmbh & Co. Kgaa | Billes de chitosane et charges comprenant de telles billes |
| EP2605746A2 (fr) | 2010-08-19 | 2013-06-26 | Merz Pharma GmbH & Co. KGaA | Composition d'agent de remplissage comprenant des bêta-glucanes |
| US8528519B2 (en) | 2010-10-27 | 2013-09-10 | Mcalister Technologies, Llc | Integrated fuel injector igniters suitable for large engine applications and associated methods of use and manufacture |
| US8091528B2 (en) | 2010-12-06 | 2012-01-10 | Mcalister Technologies, Llc | Integrated fuel injector igniters having force generating assemblies for injecting and igniting fuel and associated methods of use and manufacture |
| WO2012112615A1 (fr) | 2011-02-14 | 2012-08-23 | Mcalister Technologies, Llc | Moteurs multiplicateurs de couple |
| EP2678049A1 (fr) | 2011-02-22 | 2014-01-01 | Merz Pharma GmbH & Co. KGaA | Formation in situ d'une charge |
| EP2742218A4 (fr) | 2011-08-12 | 2015-03-25 | Mcalister Technologies Llc | Systèmes et procédés pour l'amélioration du refroidissement d'un moteur et de la production d'énergie |
| US8919377B2 (en) | 2011-08-12 | 2014-12-30 | Mcalister Technologies, Llc | Acoustically actuated flow valve assembly including a plurality of reed valves |
| AU2012341502B2 (en) * | 2011-11-25 | 2016-05-26 | Otsuka Pharmaceutical Factory, Inc. | Pharmaceutical composition useful for adhesion prevention or hemostasis |
| WO2013102247A1 (fr) | 2012-01-02 | 2013-07-11 | Ioel Dotte Echart Rubem | Générateur de cavitation hydrodynamique et hydrosonique |
| US9126176B2 (en) | 2012-05-11 | 2015-09-08 | Caisson Technology Group LLC | Bubble implosion reactor cavitation device, subassembly, and methods for utilizing the same |
| US8851047B2 (en) | 2012-08-13 | 2014-10-07 | Mcallister Technologies, Llc | Injector-igniters with variable gap electrode |
| US9169821B2 (en) | 2012-11-02 | 2015-10-27 | Mcalister Technologies, Llc | Fuel injection systems with enhanced corona burst |
| US9169814B2 (en) | 2012-11-02 | 2015-10-27 | Mcalister Technologies, Llc | Systems, methods, and devices with enhanced lorentz thrust |
| US8746197B2 (en) | 2012-11-02 | 2014-06-10 | Mcalister Technologies, Llc | Fuel injection systems with enhanced corona burst |
| US9115325B2 (en) | 2012-11-12 | 2015-08-25 | Mcalister Technologies, Llc | Systems and methods for utilizing alcohol fuels |
| US9309846B2 (en) | 2012-11-12 | 2016-04-12 | Mcalister Technologies, Llc | Motion modifiers for fuel injection systems |
| US9200561B2 (en) | 2012-11-12 | 2015-12-01 | Mcalister Technologies, Llc | Chemical fuel conditioning and activation |
| US20140131466A1 (en) | 2012-11-12 | 2014-05-15 | Advanced Green Innovations, LLC | Hydraulic displacement amplifiers for fuel injectors |
| US8800527B2 (en) | 2012-11-19 | 2014-08-12 | Mcalister Technologies, Llc | Method and apparatus for providing adaptive swirl injection and ignition |
| US9194337B2 (en) | 2013-03-14 | 2015-11-24 | Advanced Green Innovations, LLC | High pressure direct injected gaseous fuel system and retrofit kit incorporating the same |
| US8820293B1 (en) | 2013-03-15 | 2014-09-02 | Mcalister Technologies, Llc | Injector-igniter with thermochemical regeneration |
| US9562500B2 (en) | 2013-03-15 | 2017-02-07 | Mcalister Technologies, Llc | Injector-igniter with fuel characterization |
| US9732068B1 (en) | 2013-03-15 | 2017-08-15 | GenSyn Technologies, Inc. | System for crystalizing chemical compounds and methodologies for utilizing the same |
| JP6099044B2 (ja) * | 2013-03-26 | 2017-03-22 | 国立大学法人 大分大学 | 医療用組成物 |
| WO2015088983A1 (fr) | 2013-12-09 | 2015-06-18 | Cavitation Technologies, Inc. | Procédé d'extraction de glucides à partir de biomasse et conversion des glucides en biocombustibles |
| DE102014214985A1 (de) | 2014-07-30 | 2016-02-04 | Volkswagen Aktiengesellschaft | Scheibenwischeranordnung |
| CN105326809B (zh) * | 2015-10-27 | 2018-08-07 | 武汉理工大学 | 一种含有CaCO3微粒的复合天然高分子微胶囊的制备方法 |
| TWI640328B (zh) * | 2017-01-09 | 2018-11-11 | 國立成功大學 | 可供內視鏡治療術應用的即溶乾燥粉末 |
| IT201700057635A1 (it) * | 2017-05-26 | 2018-11-26 | Drugs Minerals And Generics Italia S R L In Forma Abbreviata D M G Italia S R L | Composizione per uso nel trattamento dei sintomi extra-esofagei del reflusso gastrico |
| IT202100029657A1 (it) * | 2021-11-24 | 2023-05-24 | Mauro Leonardis | Sciroppo anti-reflusso sterile senza conservanti |
| CN116236617B (zh) * | 2023-02-02 | 2025-01-03 | 深圳高性能医疗器械国家研究院有限公司 | 微球注射填充剂及其制备方法和复溶方法 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL48062C (fr) * | 1938-03-11 | 1939-10-16 | ||
| GB944705A (en) * | 1960-07-26 | 1963-12-18 | Unilever Ltd | Homogenising device and method |
| GB1173302A (en) * | 1966-07-20 | 1969-12-10 | Rolls Royce | Mixing Device and Mixing Method for Fluids |
| US3467072A (en) * | 1966-08-31 | 1969-09-16 | Energy Transform | Combustion optimizing devices and methods |
| FR2084292A5 (fr) * | 1970-03-06 | 1971-12-17 | Dresser Ind | |
| IT942173B (it) * | 1970-09-19 | 1973-03-20 | Alfa Laval Gmbh | Procedimento e dispositivo per l omogeneizzazione di liquidi immiscibili |
| US3677522A (en) * | 1970-12-02 | 1972-07-18 | Dow Chemical Co | Feeder stream mixer |
| US3937445A (en) * | 1974-02-11 | 1976-02-10 | Vito Agosta | Process and apparatus for obtaining the emulsification of nonmiscible liquids |
| US3926413A (en) * | 1975-01-20 | 1975-12-16 | Sonic Corp | Apparatus for producing acoustic vibrations in liquids |
| DE2634496C2 (de) * | 1976-07-31 | 1985-10-17 | Bayer Ag, 5090 Leverkusen | Injektor zur Begasung einer Flüssigkeit |
| US4111402A (en) * | 1976-10-05 | 1978-09-05 | Chemineer, Inc. | Motionless mixer |
| US4352883A (en) * | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
| US4344752A (en) * | 1980-03-14 | 1982-08-17 | The Trane Company | Water-in-oil emulsifier and oil-burner boiler system incorporating such emulsifier |
| US4306816A (en) * | 1980-04-04 | 1981-12-22 | Folland Corporation | Barodynamic resonator |
| US4344754A (en) * | 1981-02-20 | 1982-08-17 | Conoco Inc. | Water cooled vertical gas distributor |
| US4424208A (en) * | 1982-01-11 | 1984-01-03 | Collagen Corporation | Collagen implant material and method for augmenting soft tissue |
| US4441823A (en) * | 1982-07-19 | 1984-04-10 | Power Harold H | Static line mixer |
| US4806355A (en) * | 1983-06-06 | 1989-02-21 | Connaught Laboratories Limited | Microencapsulation of living tissue and cells |
| US4663286A (en) * | 1984-02-13 | 1987-05-05 | Damon Biotech, Inc. | Encapsulation of materials |
| FR2559855B1 (fr) * | 1984-02-21 | 1986-10-31 | Schlumberger Cie Dowell | Procede pour ameliorer les caracteristiques d'un laitier de ciment pour cimentation de puits |
| JP2739348B2 (ja) * | 1989-08-29 | 1998-04-15 | 富士写真フイルム株式会社 | fθレンズ |
| WO1991009119A1 (fr) | 1989-12-13 | 1991-06-27 | Trancel Corporation | Microcapsules d'alginate ameliorees et procedes pour leur fabrication et leur utilisation |
| US5302325A (en) * | 1990-09-25 | 1994-04-12 | Praxair Technology, Inc. | In-line dispersion of gas in liquid |
| US5800829A (en) * | 1991-04-25 | 1998-09-01 | Brown University Research Foundation | Methods for coextruding immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core |
| US5868495A (en) * | 1991-07-08 | 1999-02-09 | Hidalgo; Oscar Mario Guagnelli | Method for treating fluent materials |
| US5318780A (en) * | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
| WO1994013392A1 (fr) * | 1991-11-29 | 1994-06-23 | Ki N Proizv Ob | Procede et dispositif permettant d'obtenir un systeme a libre dispersion |
| US6537574B1 (en) * | 1992-02-11 | 2003-03-25 | Bioform, Inc. | Soft tissue augmentation material |
| US7060287B1 (en) * | 1992-02-11 | 2006-06-13 | Bioform Inc. | Tissue augmentation material and method |
| DE4204012A1 (de) * | 1992-02-12 | 1993-08-19 | Ulrich Prof Dr Zimmermann | Mitogenfreie substanz, deren herstellung und verwendung |
| US5326468A (en) * | 1992-03-02 | 1994-07-05 | Cox Dale W | Water remediation and purification method and apparatus |
| DE784487T1 (de) * | 1993-03-19 | 1999-11-04 | Q-Med Ab, Uppsala | Ein präparat und ein verfahren zur gewebevermehrung |
| US5709854A (en) * | 1993-04-30 | 1998-01-20 | Massachusetts Institute Of Technology | Tissue formation by injecting a cell-polymeric solution that gels in vivo |
| US5876742A (en) | 1994-01-24 | 1999-03-02 | The Regents Of The University Of California | Biological tissue transplant coated with stabilized multilayer alginate coating suitable for transplantation and method of preparation thereof |
| US5969207A (en) * | 1994-02-02 | 1999-10-19 | Kozyuk; Oleg V. | Method for changing the qualitative and quantitative composition of a mixture of liquid hydrocarbons based on the effects of cavitation |
| US5720551A (en) * | 1994-10-28 | 1998-02-24 | Shechter; Tal | Forming emulsions |
| US5658329A (en) | 1995-02-14 | 1997-08-19 | Mentor Corporation | Filling material for soft tissue implant prostheses and implants made therewith |
| US5916790A (en) * | 1995-03-03 | 1999-06-29 | Metabolex, Inc. | Encapsulation compositions, and methods |
| US6214331B1 (en) * | 1995-06-06 | 2001-04-10 | C. R. Bard, Inc. | Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained |
| WO1996039464A1 (fr) * | 1995-06-06 | 1996-12-12 | C.R. Bard, Inc. | Procede de preparation de dispersions aqueuses de particules de polymeres hydrosolubles et particules ainsi obtenues |
| WO1997030292A1 (fr) * | 1996-02-15 | 1997-08-21 | Oleg Vyacheslavovich Kozyuk | Procede et dispositif d'obtention d'un systeme a dispersion libre dans un liquide |
| JP4335316B2 (ja) * | 1996-09-19 | 2009-09-30 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | アルギネートまたは修飾アルギネートのようなポリサッカライドを含むポリマー |
| US5785642A (en) * | 1996-10-18 | 1998-07-28 | Micro Therapeutics, Inc. | Methods for treating urinary incontinence in mammals |
| US6224893B1 (en) * | 1997-04-11 | 2001-05-01 | Massachusetts Institute Of Technology | Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering |
| US5937906A (en) * | 1997-05-06 | 1999-08-17 | Kozyuk; Oleg V. | Method and apparatus for conducting sonochemical reactions and processes using hydrodynamic cavitation |
| US5971601A (en) * | 1998-02-06 | 1999-10-26 | Kozyuk; Oleg Vyacheslavovich | Method and apparatus of producing liquid disperse systems |
| SE9802350D0 (sv) * | 1998-07-01 | 1998-07-01 | Borealis As | Mixing device |
| US6605294B2 (en) * | 1998-08-14 | 2003-08-12 | Incept Llc | Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels |
| DE19836960A1 (de) | 1998-08-14 | 2000-02-17 | Ulrich Zimmermann | Verfahren zur Gewinnung hochgereinigter Alginate |
| US6027241A (en) * | 1999-04-30 | 2000-02-22 | Komax Systems, Inc. | Multi viscosity mixing apparatus |
| US6279611B2 (en) * | 1999-05-10 | 2001-08-28 | Hideto Uematsu | Apparatus for generating microbubbles while mixing an additive fluid with a mainstream liquid |
| US6264113B1 (en) * | 1999-07-19 | 2001-07-24 | Steelcase Inc. | Fluid spraying system |
| US6422735B1 (en) * | 1999-09-20 | 2002-07-23 | John Stewart Lang | Hydraulic jet flash mixer with open injection port in the flow deflector |
| CA2296167A1 (fr) * | 2000-01-17 | 2001-07-17 | Timothy Donald Mossip | Agitateur vertical statique cannele |
| DE10009326A1 (de) * | 2000-02-28 | 2001-08-30 | Rs Kavitationstechnik | Kavitationsmischer |
| US6649384B2 (en) * | 2000-07-05 | 2003-11-18 | Islet Technology, Inc. | System and method for encapsulating biological material by applying electrostatic charge to capsules |
| US6502979B1 (en) * | 2000-11-20 | 2003-01-07 | Five Star Technologies, Inc. | Device and method for creating hydrodynamic cavitation in fluids |
| FR2816847B1 (fr) * | 2000-11-22 | 2006-07-14 | Assist Publ Hopitaux De Paris | Biomateriaux polymeriques poreux, procede de preparation et utilisations |
| US6830370B1 (en) * | 2000-11-28 | 2004-12-14 | Ohr Co., Ltd. | Cavitation generating device and fluid mixing device using the device |
| US6913765B2 (en) * | 2001-03-21 | 2005-07-05 | Scimed Life Systems, Inc. | Controlling resorption of bioresorbable medical implant material |
| MXPA01011542A (es) * | 2001-11-13 | 2003-05-22 | Alcon Inc | Regeneracion del cartilago articular da°ado por la osteoartritis de grado i y ii, mediante la aplicacion intra-articular de una mezcla de hialuronato de sodio y de condroitin sulfato en un vehiculo de gel. |
| WO2003072157A1 (fr) * | 2002-02-21 | 2003-09-04 | Encelle, Inc. | Matrices d'hydrogel bioactives immobilisees utilisees en tant que revetements de surface |
| AU2003223372A1 (en) * | 2002-03-29 | 2003-10-13 | Boston Scientific Limited | Tissue treatment |
| US6802639B2 (en) * | 2002-10-15 | 2004-10-12 | Five Star Technologies, Inc. | Homogenization device and method of using same |
| FR2849602B1 (fr) * | 2003-01-06 | 2008-09-05 | Assist Publ Hopitaux De Paris | Solutions injectables gelifiantes a base de polymeres reticules et non reticules, et leurs applications |
| US20040251566A1 (en) * | 2003-06-13 | 2004-12-16 | Kozyuk Oleg V. | Device and method for generating microbubbles in a liquid using hydrodynamic cavitation |
| DE102004019241A1 (de) | 2004-04-16 | 2005-11-03 | Cellmed Ag | Injizierbare vernetzte und unvernetzte Alginate und ihre Verwendung in der Medizin und in der ästhetischen Chirurgie |
| US7207712B2 (en) * | 2004-09-07 | 2007-04-24 | Five Star Technologies, Inc. | Device and method for creating hydrodynamic cavitation in fluids |
| US7247244B2 (en) * | 2004-10-20 | 2007-07-24 | Five Star Technologies, Inc. | Water treatment processes and devices utilizing hydrodynamic cavitation |
| EP1813294B1 (fr) * | 2004-11-18 | 2010-03-24 | Keio University | Preventif d adhesion et procede visant a prevenir l' adhesion |
| EP1903009A4 (fr) * | 2005-06-10 | 2013-10-02 | Jfe Eng Corp | Appareil et procédé de traitement d'eau de lestage |
| DE102005037026B4 (de) * | 2005-08-05 | 2010-12-16 | Cavitator Systems Gmbh | Kavitationsmischer |
| US7833421B2 (en) * | 2005-10-25 | 2010-11-16 | Elmar Huymann | Degermination through cavitation |
| US7708453B2 (en) * | 2006-03-03 | 2010-05-04 | Cavitech Holdings, Llc | Device for creating hydrodynamic cavitation in fluids |
| CA2732957C (fr) * | 2007-08-07 | 2015-11-24 | Nathaniel Hughes | Melangeur moleculaire et reacteur catalytique |
| US7762715B2 (en) * | 2008-10-27 | 2010-07-27 | Cavitation Technologies, Inc. | Cavitation generator |
-
2004
- 2004-04-16 DE DE102004019241A patent/DE102004019241A1/de not_active Withdrawn
-
2005
- 2005-03-02 WO PCT/EP2005/002201 patent/WO2005105167A1/fr not_active Ceased
- 2005-03-02 US US10/599,980 patent/US8163714B2/en not_active Expired - Fee Related
- 2005-03-02 EP EP05707688A patent/EP1735020A1/fr not_active Withdrawn
- 2005-03-02 BR BRPI0509924-2A patent/BRPI0509924A/pt active Search and Examination
-
2007
- 2007-02-27 US US11/679,665 patent/US20070189114A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2005105167A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005105167A1 (fr) | 2005-11-10 |
| DE102004019241A1 (de) | 2005-11-03 |
| US20070189114A1 (en) | 2007-08-16 |
| BRPI0509924A (pt) | 2007-09-18 |
| US20070179117A1 (en) | 2007-08-02 |
| US8163714B2 (en) | 2012-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1735020A1 (fr) | Alginates reticules et non reticules, injectables, et leur utilisation en medecine et en chirurgie esthetique | |
| DE69922352T2 (de) | Implantierbare partikel zur erhöhung des gewebevolumens und zur behandlung von gastroösophagalreflux, inkontinenz und hautfalten | |
| JP7263459B2 (ja) | 癒着予防のためのハイドロゲル膜 | |
| EP2082755A1 (fr) | Implants in situ d'alginate en réseau monolithiques | |
| DE69530919T2 (de) | Beigeordnetes polymersystem zur verwendung mit einer medizinischen vorrichtung | |
| DE69318835T2 (de) | Behandlung einer refluxstörung durch injektion von mikropartikeln | |
| DE69628783T2 (de) | Hydrogelbildende, selbst-solvatisierende, absorbierbare Polyestercopolymere sowie Verfahren zu deren Verwendung | |
| US5633001A (en) | Composition and a method for tissue augmentation | |
| DE60105884T2 (de) | Mittel und Verfahren zum Verformen von Weichgewebe | |
| DE69929278T2 (de) | Hydrogelbildende, selbst-solvatisierende, absorbierbare Polyestercopolymere sowie Verfahren zu deren Verwendung | |
| DE69737909T3 (de) | Polymerisierbare biologisch abbaubare polymere mit carbonat-oder dioxanonbindungen | |
| JPH11505734A (ja) | 注入可能なヒドロゲル組成物 | |
| EP2416741B1 (fr) | Systèmes d'alginate coagulant in situ | |
| DE60110413T2 (de) | Polyacrylamid hydrogel und seine verwendung als endoprothese | |
| DE3486088T2 (de) | Einspritzbare physiologisch unbedenkliche polymerzusammensetzungen. | |
| US9017709B2 (en) | Composition comprising polymeric, water-insoluble, anionic particles, processes and uses | |
| CN116983466A (zh) | 一种医用凝胶敷料及其制备方法和应用 | |
| DE69302262T2 (de) | Kollagenmikrokapseln enthaltende injezierbare zusammensetzung | |
| CN110997021B (zh) | 包含聚(1,3-三亚甲基碳酸酯)的可再吸收可生物降解的医药和化妆品组合物 | |
| US8084513B2 (en) | Implant filling material and method | |
| WO2002017816A1 (fr) | Procedes et compositions permettant une augmentation tissulaire | |
| Hapse Sandip | World Journal of Pharmaceutical Science & Technology | |
| NZ623909B2 (en) | Threads of cross-linked hyaluronic acid and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20060920 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: THUERMER, FRANK Inventor name: REINER, ROLAND Inventor name: GLOECKNER, HERMA Inventor name: GEIGLE, PETER |
|
| DAX | Request for extension of the european patent (deleted) | ||
| 17Q | First examination report despatched |
Effective date: 20080115 |
|
| APBK | Appeal reference recorded |
Free format text: ORIGINAL CODE: EPIDOSNREFNE |
|
| APBN | Date of receipt of notice of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA2E |
|
| APBR | Date of receipt of statement of grounds of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA3E |
|
| APAF | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNE |
|
| APBT | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9E |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20141001 |